Latest Dry Eye Treatments (2025)
Discover the newest FDA-approved treatments and cutting-edge technologies revolutionizing dry eye care in 2025.
The Future of Dry Eye Treatment is Here
The past few years have brought remarkable advances in dry eye treatment, with multiple new FDA approvals introducing novel mechanisms of action. These innovations offer hope for patients who haven't found relief with traditional therapies.
From nasal sprays that stimulate tear production to light-based therapies that target the root causes of meibomian gland dysfunction, today's treatments are more targeted, effective, and patient-friendly than ever before.
New treatments work through entirely different pathways than traditional options
Clinical trials show improved efficacy and faster symptom relief
Treatments address specific dry eye subtypes for personalized care
Recently Approved & Advanced Treatments
First-in-class nasal spray that stimulates the trigeminal nerve to increase natural tear production
Key Features
- Immediate increase in tear production
- No eye drops required—nasal spray application
- Twice-daily dosing
- Works through novel neurostimulation mechanism
Availability
Available now by prescription
Ideal For
Patients who struggle with eye drops or need immediate tear stimulation
Semi-fluorinated alkane eye drops that reduce tear evaporation by forming a protective layer on the tear film
Key Features
- Targets evaporative dry eye specifically
- Unique mechanism—reduces tear evaporation
- Four times daily dosing
- Preservative-free formulation
Availability
Available now by prescription
Ideal For
Patients with evaporative dry eye or meibomian gland dysfunction
First FDA-approved treatment for Demodex blepharitis, a common cause of dry eye symptoms
Key Features
- Targets Demodex mites on eyelashes
- Twice-daily for 6 weeks
- Reduces inflammation from mite infestation
- Addresses root cause of symptoms
Availability
Available now by prescription
Ideal For
Patients with Demodex blepharitis causing dry eye symptoms
Intense Pulsed Light therapy specifically optimized for dry eye treatment caused by MGD
Key Features
- Non-invasive light-based therapy
- Treats meibomian gland dysfunction
- Series of 4 treatments over 6-8 weeks
- Long-lasting results (6-12 months)
Availability
Available at The Last Optical
Ideal For
Patients with moderate to severe MGD not responding to conventional treatments
Wearable eyelid warming device that allows blinking during treatment for natural meibomian gland expression
Key Features
- Personalized heat therapy
- Allows natural blinking during treatment
- 15-minute treatment session
- Immediate improvement in gland function
Availability
Available at The Last Optical
Ideal For
Patients with meibomian gland dysfunction seeking in-office treatment
In the Pipeline: What's Coming Next
Several promising treatments are currently in clinical trials and may receive FDA approval in the coming years:
Note: Treatments in clinical trials are not yet available for patient use. We'll update this page as new treatments receive FDA approval.
Advanced Treatments at The Last Optical
We're proud to offer the latest FDA-approved treatments and advanced technologies at our Montgomery, NY location:
In-Office Procedures
- OptiLight™ IPL Therapy
- TearCare® System
- OptiPlus Treatment
- OptiLift Non-Invasive Eyelid Lift
Prescription Options
- Tyrvaya® (Varenicline Nasal Spray)
- Miebo® (Perfluorohexyloctane)
- Xdemvy® (Lotilaner)
- All traditional prescription options